WO2024254507A3 - Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20 - Google Patents

Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20 Download PDF

Info

Publication number
WO2024254507A3
WO2024254507A3 PCT/US2024/033083 US2024033083W WO2024254507A3 WO 2024254507 A3 WO2024254507 A3 WO 2024254507A3 US 2024033083 W US2024033083 W US 2024033083W WO 2024254507 A3 WO2024254507 A3 WO 2024254507A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
treatment
cell lymphomas
targeted antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033083
Other languages
English (en)
Other versions
WO2024254507A2 (fr
Inventor
Fred ASLAN
Thorsten Graef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artiva Biotherapeutics Inc
Original Assignee
Artiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artiva Biotherapeutics Inc filed Critical Artiva Biotherapeutics Inc
Publication of WO2024254507A2 publication Critical patent/WO2024254507A2/fr
Publication of WO2024254507A3 publication Critical patent/WO2024254507A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne, entre autres, des méthodes de traitement de lymphomes B avec des cellules NK et un anticorps ciblant CD20.
PCT/US2024/033083 2023-06-09 2024-06-07 Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20 Ceased WO2024254507A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507393P 2023-06-09 2023-06-09
US63/507,393 2023-06-09

Publications (2)

Publication Number Publication Date
WO2024254507A2 WO2024254507A2 (fr) 2024-12-12
WO2024254507A3 true WO2024254507A3 (fr) 2025-01-30

Family

ID=93796421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033083 Ceased WO2024254507A2 (fr) 2023-06-09 2024-06-07 Traitement de lymphomes b avec des cellules nk et un anticorps ciblant cd20

Country Status (1)

Country Link
WO (1) WO2024254507A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (fr) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133057A1 (fr) * 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Traitement du cancer par des cellules nk et un anticorps ciblant cd20
WO2022216811A2 (fr) * 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Récepteur d'antigène chimère comprenant un anticorps anti-cd19 ou un fragment de liaison à l'antigène de celui-ci et cellules tueuses naturelles le comprenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133057A1 (fr) * 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Traitement du cancer par des cellules nk et un anticorps ciblant cd20
WO2022216811A2 (fr) * 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Récepteur d'antigène chimère comprenant un anticorps anti-cd19 ou un fragment de liaison à l'antigène de celui-ci et cellules tueuses naturelles le comprenant

Also Published As

Publication number Publication date
WO2024254507A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
WO2023122755A3 (fr) Cuve à circulation et procédés
MX2022005389A (es) Terapia de celulas t con receptor de antigeno quimerico.
WO2022272292A3 (fr) Cellules ingéniérisées pour une thérapie
WO2021257989A3 (fr) Méthodes et compositions pour moduler des cellules et des membranes cellulaires
PH12021552743A1 (en) Anti-cd19 therapy in patients having a limited number of nk cells
EP4280806A3 (fr) Multicast efficace
BR112022003852A2 (pt) Métodos de preparação de células t para terapia de células t
EP4319769A4 (fr) Traitement du cancer par des cellules nk et un anticorps ciblant le cd20
WO2022150610A3 (fr) Récepteurs de lymphocytes t spécifiques à sars-cov-2, matériels correspondants et méthodes d'utilisation
EP4481850A4 (fr) Mélange silicium-carbone, son procédé de préparation et matériau actif d'anode et batterie secondaire au lithium le comprenant
EP4442815A3 (fr) Compositions et méthodes de traitement de cancers positifs à l'egfr
CR20230490A (es) Anticuerpo biespecífico anti–cldn4/anti–cd137
EP4310956A4 (fr) Composition de matériau carboné, procédé de production d'une composition de matériau carboné, électrode négative et batterie secondaire
MX2025005088A (es) Métodos para tratar cánceres
EP4383362A4 (fr) Matériau de cathode, batterie utilisant ledit matériau de cathode, et procédé de charge de batterie
WO2022212947A8 (fr) Peptides cycliques spécifiques au kras, compositions et méthodes d'utilisation et de fabrication
EP4135071A4 (fr) Matériau actif de cathode pour batterie secondaire au lithium, son procédé de préparation et batterie secondaire au lithium le comprenant
WO2023086906A3 (fr) Anticorps sirp gamma et leurs utilisations
WO2019070435A8 (fr) Méthodes d'expansion sélective de cellules exprimant un tcr avec une région constante murine
EP4207370A4 (fr) Matériau actif d'électrode positive pour accumulateur à électrolyte non aqueux et accumulateur à électrolyte non aqueux
WO2022212400A8 (fr) Méthodes de dosage et de traitement au moyen d'une combinaison d'une thérapie par inhibiteur de point de contrôle et d'une thérapie par lymphocytes car t
WO2022178211A3 (fr) Cellules immunitaires reprogrammées à axe mir200c-epcam pour une fonction antitumorale améliorée
MX2025002504A (es) Composiciones para expresión celular específica y usos de las mismas
WO2021262788A3 (fr) Cellules de nanotubes à effet tunnel et leurs procédés d'utilisation pour l'administration de biomolécules
WO2024215863A3 (fr) Inhibition de la monoacylglycérol lipase (magl)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820165

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 24820165

Country of ref document: EP

Kind code of ref document: A2